[go: up one dir, main page]

MX2012002402A - Bifidobacterium longum y trastornos gastrointestinales funcionales. - Google Patents

Bifidobacterium longum y trastornos gastrointestinales funcionales.

Info

Publication number
MX2012002402A
MX2012002402A MX2012002402A MX2012002402A MX2012002402A MX 2012002402 A MX2012002402 A MX 2012002402A MX 2012002402 A MX2012002402 A MX 2012002402A MX 2012002402 A MX2012002402 A MX 2012002402A MX 2012002402 A MX2012002402 A MX 2012002402A
Authority
MX
Mexico
Prior art keywords
bifidobacterium longum
disorders
functional
present
relates
Prior art date
Application number
MX2012002402A
Other languages
English (en)
Inventor
Peter Mclean
Gabriela Bergonzelli De Gonda
Stephen Michael Collins
Premysl Bercik
Elena Verdu De Bercik
Original Assignee
Nestec Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41508246&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012002402(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nestec Sa filed Critical Nestec Sa
Publication of MX2012002402A publication Critical patent/MX2012002402A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K10/00—Animal feeding-stuffs
    • A23K10/10—Animal feeding-stuffs obtained by microbiological or biochemical processes
    • A23K10/16—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
    • A23K10/18—Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions of live microorganisms
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/01—Hydrolysed proteins; Derivatives thereof
    • A61K38/012—Hydrolysed proteins; Derivatives thereof from animals
    • A61K38/018—Hydrolysed proteins; Derivatives thereof from animals from milk
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/163—Sugars; Polysaccharides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/51—Bifidobacterium
    • A23V2400/533—Longum

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Polymers & Plastics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Nutrition Science (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Animal Husbandry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere generalmente al campo de bacterias probióticas. Se refiere en particular a Bifidobactrium Iongum, tal como Bifidobactrium Iongum ATCC BAA-999, y a su uso en composiciones que pueden ingerirse. La composición descrita en la presente invención puede usarse para tratar o prevenir trastornos gastrointestinales funcionales.
MX2012002402A 2009-08-25 2010-08-24 Bifidobacterium longum y trastornos gastrointestinales funcionales. MX2012002402A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09168590.9A EP2289527B1 (en) 2009-08-25 2009-08-25 Bifidobacterium longum and functional GI disorders
PCT/EP2010/062320 WO2011023689A1 (en) 2009-08-25 2010-08-24 Bifidobacterium longum and functional gi disorders

Publications (1)

Publication Number Publication Date
MX2012002402A true MX2012002402A (es) 2012-04-02

Family

ID=41508246

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012002402A MX2012002402A (es) 2009-08-25 2010-08-24 Bifidobacterium longum y trastornos gastrointestinales funcionales.

Country Status (17)

Country Link
US (3) US10028981B2 (es)
EP (2) EP2289527B1 (es)
JP (4) JP2013503130A (es)
CN (2) CN102573863A (es)
AU (1) AU2010288546B2 (es)
BR (1) BR112012004046B1 (es)
CA (1) CA2772163C (es)
CL (1) CL2012000487A1 (es)
DK (1) DK2289527T3 (es)
ES (1) ES2664828T3 (es)
IN (1) IN2012DN01638A (es)
MX (1) MX2012002402A (es)
RU (1) RU2012111253A (es)
SG (1) SG178499A1 (es)
TR (1) TR201807143T4 (es)
WO (1) WO2011023689A1 (es)
ZA (1) ZA201202155B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2110028A1 (en) 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
US9173910B2 (en) 2012-02-29 2015-11-03 The General Hospital Corporation Compositions of microbiota and methods related thereto
US11179427B2 (en) 2013-01-21 2021-11-23 Eth Zurich Baby food composition comprising viable propionic acid-producing bacteria
CN105407728A (zh) 2013-07-21 2016-03-16 霍勒拜欧姆公司 用于微生物组表征、监测和治疗的方法和系统
US20150305385A1 (en) * 2014-04-25 2015-10-29 Mead Johnson Nutrition Company Pediatric nutritional composition with human milk oligosaccahrides, prebiotics and probiotics
JP6868562B2 (ja) 2014-10-31 2021-05-19 ペンデュラム セラピューティクス， インコーポレイテッド 障害の微生物的処置および診断に関する方法および組成物
EP3294308A4 (en) 2015-05-14 2019-03-06 University of Puerto Rico PROCESS FOR RECOVERING THE BIOZOOSE OF NEWBORN
US11660322B2 (en) 2015-06-11 2023-05-30 Societe Des Produits Nestle S.A. Dietary supplement
CA2994352A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to optimize breastfeeding
BR112018000934B1 (pt) * 2015-08-31 2022-02-01 Société des Produits Nestlé S.A. Usos de bifidobacterium longum para tratar ou prevenir sintomas depressivos
CA2994347A1 (en) * 2015-08-31 2017-03-09 Nestec S.A. Methods and compositions using bifidobacterium longum to modulate emotional reactivity and treat or prevent sub-clinical mood disturbances
ES2950489T3 (es) 2015-10-28 2023-10-10 Glycom As Composición sintética y método para modular los trastornos de la emoción y del ánimo
US10835545B2 (en) 2015-10-28 2020-11-17 Glycom A/S Synthetic composition and method for modulating brain function and behaviour
WO2017117142A1 (en) 2015-12-28 2017-07-06 New York University Device and method of restoring microbiota of newborns
JP6353478B2 (ja) * 2016-03-28 2018-07-04 日清食品ホールディングス株式会社 セロトニン分泌促進能力を有するビフィズス菌
CN107050062A (zh) * 2016-11-08 2017-08-18 江西益盟科技有限公司 治疗便秘的乳酸菌组合物及其制备方法
CN106579414A (zh) * 2016-12-26 2017-04-26 北京康比特体育科技股份有限公司 一种缓解运动性腹泻的组合物
US11590179B2 (en) 2017-02-28 2023-02-28 Precisionbiotics Group Limited Bifidobacterium longum able to beneficially modulate immune response to respiratory virus infection
MX379160B (es) * 2017-02-28 2025-03-11 Alimentary Health Ltd Bifidobacterium longum capaz de modular beneficiosamente la respuesta inmune contra una infección respiratoria por virus.
MX2019013143A (es) * 2017-05-05 2020-07-14 Nestle Sa Tratamiento de colicos infantiles.
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
JP7280069B2 (ja) 2018-03-28 2023-05-23 森永乳業株式会社 機能性消化管障害予防又は改善用組成物、並びに、該機能性消化管障害予防又は改善用組成物を用いた医薬品組成物及び飲食品組成物
EP3994163A1 (en) * 2019-07-01 2022-05-11 Société des Produits Nestlé S.A. Serpin production
JP2021014421A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 Ｑｏｌ改善剤
JP2021014422A (ja) * 2019-07-11 2021-02-12 日清ファルマ株式会社 便性改善剤
CN111187734A (zh) * 2019-12-25 2020-05-22 生合生物科技（扬州）有限公司 长双歧杆菌bl986、由其制备的冻干粉及冻干粉的应用
CN115666608A (zh) * 2020-05-20 2023-01-31 雀巢产品有限公司 通过长双歧杆菌提高不溶性纤维的发酵能力和短链脂肪酸的产生

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH637297A5 (fr) 1978-12-05 1983-07-29 Nestle Sa Microbille comprenant un microorganisme et son procede de fabrication.
ID29150A (id) 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
DE10008279A1 (de) * 2000-02-23 2001-08-30 Meggle Gmbh Milchzucker enthaltende Zusammensetzung
US20020044988A1 (en) * 2000-08-22 2002-04-18 Fuchs Eileen C. Nutritional composition and method for improving protein deposition
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
EP1429620A1 (en) * 2001-08-31 2004-06-23 Nutricopia, Inc. Nutritional frozen dessert and methods of menufacture
EP1384483A1 (en) 2002-07-23 2004-01-28 Nestec S.A. Probiotics for treatment of irritable bowel disease (IBS) through improvement of gut neuromuscular function
US20050180962A1 (en) * 2003-01-30 2005-08-18 Eyal Raz Inactivated probiotic bacteria and methods of use thereof
JP2004262773A (ja) * 2003-02-17 2004-09-24 Ryoshoku Kenkyukai 免疫機能改善を目的としたビフィズス菌製剤
US20040265279A1 (en) * 2003-05-08 2004-12-30 Timothy Dinan Probiotics in the treatment of atypical depression and other disorders characterized by hypothalamic pitiuitary-adrenal axis over-activity
NZ544726A (en) * 2003-06-23 2009-05-31 Nestec Sa Infant or follow-on formula
US20050100559A1 (en) * 2003-11-07 2005-05-12 The Procter & Gamble Company Stabilized compositions comprising a probiotic
US20060093592A1 (en) * 2004-10-04 2006-05-04 Nutracea Synbiotics
US8134942B2 (en) * 2005-08-24 2012-03-13 Avaak, Inc. Communication protocol for low-power network applications and a network of sensors using the same
WO2007054208A1 (en) * 2005-11-14 2007-05-18 Unilever N.V. Edible product containing ginseng polysaccharides and beneficial bacteria
JP2007169200A (ja) * 2005-12-21 2007-07-05 Morinaga Milk Ind Co Ltd インフルエンザ感染予防のための医薬及び飲食品
ES2381211T3 (es) * 2006-02-15 2012-05-24 Nestec S.A. Uso del Bifidobacterium longum para prevenir y tratar inflamaciones
US9005682B2 (en) 2006-03-07 2015-04-14 Nestec S.A. Synbiotic mixture
EP1961308A1 (en) * 2007-02-21 2008-08-27 Nestec S.A. Nutritionally balanced frozen dessert
EP1974735A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Reduction of risk of diarrhoea
EP1974743A1 (en) * 2007-03-28 2008-10-01 Nestec S.A. Probiotics to Improve Gut Microbiota
WO2009071086A2 (en) * 2007-12-06 2009-06-11 Arla Foods Amba Probiotic bacteria and regulation of fat storage
CN101939000A (zh) * 2007-12-17 2011-01-05 佛罗里达大学研究基金会有限公司 用于治疗病理性眼部血管增生的物质和方法
EP2110028A1 (en) * 2008-04-15 2009-10-21 Nestec S.A. Bifidobacterium longum and hippocampal BDNF expression
WO2010008272A1 (en) * 2008-07-15 2010-01-21 N.V. Nutricia Treatment of gut motility disorders
ES2664828T3 (es) 2009-08-25 2018-04-23 Nestec S.A. Bifidobacterium longum y trastornos GI funcionales
US11400123B2 (en) * 2018-01-29 2022-08-02 Precisionbiotics Group Limited Combination product for prophylaxis and treatment of irritable bowel syndrome

Also Published As

Publication number Publication date
ES2664828T3 (es) 2018-04-23
US20120230956A1 (en) 2012-09-13
DK2289527T3 (en) 2018-04-23
CA2772163C (en) 2017-11-07
BR112012004046B1 (pt) 2021-02-17
JP7096652B6 (ja) 2022-08-01
JP2020183385A (ja) 2020-11-12
JP2013503130A (ja) 2013-01-31
AU2010288546B2 (en) 2015-08-20
JP2018048112A (ja) 2018-03-29
EP2289527A1 (en) 2011-03-02
SG178499A1 (en) 2012-04-27
CA2772163A1 (en) 2011-03-03
US20190134104A1 (en) 2019-05-09
WO2011023689A1 (en) 2011-03-03
BR112012004046A2 (pt) 2017-05-30
AU2010288546A1 (en) 2012-03-22
US10028981B2 (en) 2018-07-24
CN102573863A (zh) 2012-07-11
RU2012111253A (ru) 2013-10-10
US11957720B2 (en) 2024-04-16
US20220280576A1 (en) 2022-09-08
JP7096652B2 (ja) 2022-07-06
CL2012000487A1 (es) 2012-08-31
JP2016074682A (ja) 2016-05-12
TR201807143T4 (tr) 2018-06-21
EP2289527B1 (en) 2018-02-21
EP2470188A1 (en) 2012-07-04
IN2012DN01638A (es) 2015-06-05
US11452745B2 (en) 2022-09-27
ZA201202155B (en) 2014-09-25
CN106072658A (zh) 2016-11-09

Similar Documents

Publication Publication Date Title
IN2012DN01638A (es)
GB2480042A (en) Prebiotic formulations and methods of use
UA109876C2 (uk) Композиція, що містить bifidobacterium longum cncm i-2618, для лікування та профілактики імунних розладів
GB2511993A (en) Prebiotic formulations and methods of use
PH12013500931A1 (en) Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
UA100551C2 (en) Synbiotic mixture
UA107711C2 (en) Use of lactobacilli inhibiting gas producing coliform bacteria isolated from infants affected by colic
IN2012DN02463A (es)
MX2011009539A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso.
NZ709392A (en) Synergistic bacterial compositions and methods of production and use thereof
WO2012112777A3 (en) Biosynthesis of human milk oligosaccharides in engineered bacteria
MY158310A (en) Prevention and treatment of allergic diarrhoea
ATE551063T1 (de) Verwendung von bifidobacterium longum zur prophylaxe und behandlung von entzündungen
PL2513023T3 (pl) Kompozycje i zastosowania cis-1,1,1,4,4,4-heksafluoro-2-butenu
MX346458B (es) Composicion probiotica para la salud bucal.
MX2010008137A (es) Bacterias no patogenas y/o atenuadas capaces de inducir apoptosis en macrofagos, proceso de fabricacion y su usos.
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
WO2010008491A3 (en) Lactose compositions with decreased lactose content
EA201291441A1 (ru) Пробиотические штаммы для применения при улучшении состояния кишечной нервной системы
PT2173196E (pt) Uso de probi?ticos e fibras para a diarreia
MX2011005527A (es) Uso de la bacteria de acido lactico para tratar o prevenir el eczema.
MX342947B (es) Tratamiento de diabetes tipo 2.
PH12013500811A1 (en) Extruded non-replicating probiotic micro-organisms and their health benefits
GEP201606589B (en) Novel bacterium and extracts of said bacterium and the use of same in dermatology
MX360411B (es) Uso de tiosulfato para potenciar el efecto anti-patogenico de los lactobacilos.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal